Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study

Diabetes, Obesity & Metabolism
B SillarsTimothy M E Davis

Abstract

To determine whether combination of metformin-sulphonylurea is associated with an increased risk of cardiovascular disease (CVD) and mortality in an urban community-based cohort of type 2 patients. We studied 1271 (98.2%) of 1294 type 2 participants in the observational Fremantle Diabetes Study (mean age 64.2 years, 48.8% males) who had detailed diabetes-specific therapy recorded at baseline and complete follow-up data. Mortality and hospital discharge data were collected over 13 174 patient-years (mean +/- SD: 10.4 +/- 3.9 years). Cox proportional hazards modelling was used to determine whether baseline diabetes treatments were independently associated with cardiovascular mortality, hospitalization for/death from CVD or all-cause mortality after adjustment for other explanatory variables. During follow-up, 523 deaths occurred (41.1%) of which 269 (51.4%) were attributed to CVD. Hospitalization for CVD as principal diagnosis occurred at least once for 481 (37.8%) participants. In Kaplan-Meier analyses, there were significant differences in cardiovascular mortality, hospitalization for/death from CVD and all-cause mortality between diabetes therapy groups (p < 0.001). Compared with diet and metformin monotherapy, those treated w...Continue Reading

References

Nov 27, 1999·Australian and New Zealand Journal of Public Health·C D HolmanM S Hobbs
Oct 29, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·T M DavisI R Mackay
Jan 30, 2004·The Medical Journal of Australia·Timothy M E DavisUNKNOWN United Kingdom Prospective Diabetes Study
May 11, 2004·Diabetes/metabolism Research and Reviews·Martin Gulliford, Radoslav Latinovic
Mar 25, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·J A JohnsonS R Majumdar
Feb 22, 2008·Cardiovascular Drugs and Therapy·Partha Kar, Richard I G Holt
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil

❮ Previous
Next ❯

Citations

Feb 5, 2014·Expert Review of Clinical Pharmacology·Emily Weidman-EvansJeffery D Evans
Mar 4, 2014·Endocrinology and Metabolism Clinics of North America·Magdalene M Szuszkiewicz-Garcia, Jaime A Davidson
Mar 1, 2016·Expert Review of Clinical Pharmacology·Awadhesh Kumar Singh, Ritu Singh
Sep 28, 2012·Diabetes, Obesity & Metabolism·D S H Bell
May 15, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·O J PhungS N Rajpathak
Jun 13, 2015·European Heart Journal·Ele Ferrannini, Ralph A DeFronzo
Dec 4, 2014·The Lancet. Diabetes & Endocrinology·Scot H SimpsonTravis R Featherstone
Mar 13, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Elisabetta PatornoJohn D Seeger
Aug 2, 2013·Diabetes Care·Ralph A DeFronzoMuhammad Abdul-Ghani
Apr 15, 2014·Journal of the American Podiatric Medical Association·Jodi Lynn Gallant, Michael Raymond Pierrynowski
Jan 8, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Thomas ForstAxel Haupt
Jun 3, 2018·Hormones : International Journal of Endocrinology and Metabolism·Panagiotis AnagnostisAsterios Karagiannis

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.